PEP/NEWS — Peptide intel. Daily.

Get LMNT Electrolytes & Receive a FREE Sample Flavors Pack: http://drinklmnt.com/thomas This video does contain a paid partnership with a brand that helps to support this channel. It is because of brands like this that we are able to provi

In this episode, Dr. Rena Malik and Sue Goldstein discuss what makes sex unsatisfying for women, touching on pain, arousal, and breaking myths about lubricants and sex toys. They highlight the importance of communication, awareness around m

Book your free discovery call *HERE:* https://drjonesdc.com/ytfm I’ve seen too many people get stuck treating reflux like it’s only an acid problem. The truth is chronic reflux often comes from three connected layers: damaged digestive ti

Harvard Health Publishing released its first special report dedicated entirely to longevity science. For a field that spent years straddling credibility lines, it's a notable signal that geroscience is moving into mainstream medicine.

Cutting methionine — an amino acid found in meat and eggs — extended lifespan in yeast by activating autophagy (the cell's self-cleaning process) through a methylation pathway. The mechanistic detail here is sharper than most restriction studies.

Phosphatidylcholine — the most abundant lipid in mitochondrial membranes — declines with age. Scientists found this loss drives mitochondrial dysfunction, pointing to a concrete molecular target for anti-aging intervention.

New research shows omega-3 PUFAs may help slow chronic kidney disease by reducing cellular senescence — the buildup of aged, non-functioning cells that drive inflammation. Prior trial results on omega-3s and kidneys had been mixed; this mechanism explains why.

Korean pharma giant Daewoong bought Turn Biotechnologies' partial cellular reprogramming platform. The ERA platform uses mRNA to push cells toward a younger state without fully resetting them — a key distinction in the reprogramming safety debate.

Retro Biosciences — backed by $1.8 billion and OpenAI's Sam Altman — is advancing deeper into human Alzheimer's testing. The company's thesis: treat aging itself before the damage fully arrives, not after.

MBX Biosciences will present at the Jefferies 2026 Global Healthcare Conference with updates on its peptide-based metabolic pipeline. The company is one of the few pure-play peptide firms with public visibility at major institutional healthcare events.

Biogen and Ionis reported the first Phase 2 evidence that reducing tau protein — not just amyloid — may slow cognitive decline in early Alzheimer's. Decades of amyloid-only focus may finally be giving way to a broader target landscape.

Virta Health CEO Sami Inkinen details how the company has reversed type 2 diabetes in over 100,000 patients using nutrition and technology — without drugs. The metabolic mechanisms are directly relevant to GLP-1 research and the broader metabolic health conversation.

This second installment covers how tumors spread and which molecular brakes normally stop them. It then maps the first specific peptides being studied in these pathways — a useful reference for anyone tracking the oncology-peptide intersection.

The most practically useful installment of the series. It addresses GH secretagogue risk directly — including what washout periods look like in the literature and how researchers are thinking about the risk-benefit landscape.